Search alternatives:
significantly improves » significantly improved (Expand Search), significantly improve (Expand Search), significant improvements (Expand Search)
improves decrease » improves disease (Expand Search), improve disease (Expand Search), improved urease (Expand Search)
weaker decrease » greater decrease (Expand Search), teer decrease (Expand Search), water decreases (Expand Search)
mean decrease » a decrease (Expand Search)
Showing 41 - 60 results of 28,562 for search '(( significantly ((weaker decrease) OR (mean decrease)) ) OR ( significantly improves decrease ))*', query time: 1.14s Refine Results
  1. 41
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 42
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 43
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 44
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 45
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 46
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 47
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 48
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 49
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 50
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 51
    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.

    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 52
    Inhibiting caspase-3 did not improve oxidative stress in red blood cells.

    Inhibiting caspase-3 did not improve oxidative stress in red blood cells. by Lu Han (151620)

    Published 2023
    Save to List
    Saved in:
  13. 53
    Generalizable improvement of QOL measures on day 7 vs. infusion day.

    Generalizable improvement of QOL measures on day 7 vs. infusion day. by Jordan K. Abbott (8934239)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  14. 54
    Starvation improves locomotory capacity and decreases the number of α-synuclein-YFP aggregates of transgenic <i>C. elegans</i> through LMP-1 dependent mechanism.

    Starvation improves locomotory capacity and decreases the number of α-synuclein-YFP aggregates of transgenic <i>C. elegans</i> through LMP-1 dependent mechanism. by María Gallardo-Campos (22170919)

    Published 2025
    Save to List
    Saved in:
  15. 55
    Annual number of outpatient visits in all eyes.

    Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 56
    Time course of optical coherence tomography and fundus findings in a representative non-recurrent eye.

    Time course of optical coherence tomography and fundus findings in a representative non-recurrent eye. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 57
    Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups.

    Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 58
    Time course of best-corrected visual acuity (BCVA) in all eyes.

    Time course of best-corrected visual acuity (BCVA) in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 59
    Annual number of outpatient visits in recurrence and non-recurrence groups.

    Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 60
    Time course of central retinal thickness (CRT) in all eyes.

    Time course of central retinal thickness (CRT) in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: